Aspen Pharmacare Holdings (JSE:APN) Tariff Resilience Score: 7/10 (As of Jul. 13, 2026)


JSE:APN Aspen Pharmacare Holdings Ltd JSE:APN
74 GF Score
Price R151.05
GF Value R170.77
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Tariff Resilience Score?

Aspen Pharmacare Holdings JSE:APN +2.70% 74 Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus rates JSE:APN with a GF Score™ of 74/100 and a GF Value™ of R170.77 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks better than 97.08% on this metric.

Aspen Pharmacare Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Aspen Pharmacare Holdings has Aspen Pharmacare has a strong global presence with manufacturing in low-tariff regions. Its diversified sales markets and historical resilience to tariff changes enhance its score. The pharmaceutical industry often benefits from exemptions, reducing vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aspen Pharmacare Holdings might have Highly Resilient.

Aspen Pharmacare Holdings  (JSE:APN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aspen Pharmacare Holdings Tariff Resilience Score Related Terms

JSE:APN vs ZTS, UTHR, VTRS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Tariff Resilience Score falls into.


JSE:APN
74GF Score
Aspen Pharmacare Holdings Ltd JSE:APN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Aspen Pharmacare Holdings (JSE:APN) has a Tariff Resilience Score of 7 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Aspen Pharmacare Holdings' Tariff Resilience Score too high?
Aspen Pharmacare Holdings' current Tariff Resilience Score is 7. Based on the distribution chart, Aspen Pharmacare Holdings ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aspen Pharmacare Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #30 out of 1029 companies for Tariff Resilience Score. This places Aspen Pharmacare Holdings in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Aspen Pharmacare Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R170.77, compared to a current price of R151.05 — trading 11.5% below its estimated fair value. The current Tariff Resilience Score is 7. Aspen Pharmacare Holdings' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of R151.05 is trading 11.5% below its estimated GF Value™ of R170.77. GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.

Key valuation signals for JSE:APN:

  • Tariff Resilience Score: 7
  • GF Value™: R170.77 vs. price of R151.05 (11.5% below fair value)
  • GF Score™: 74/100 with 10 warning signs

No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
74GF Score

Get the complete analysis for JSE:APN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R151.05
Price
R170.77
GF Value